Cargando…
Recent advances in drug delivery systems for targeting brain tumors
Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the over...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828736/ https://www.ncbi.nlm.nih.gov/pubmed/36597214 http://dx.doi.org/10.1080/10717544.2022.2154409 |
_version_ | 1784867334403391488 |
---|---|
author | Zhao, Yi Yue, Ping Peng, Yao Sun, Yuanyuan Chen, Xing Zhao, Ze Han, Bingjie |
author_facet | Zhao, Yi Yue, Ping Peng, Yao Sun, Yuanyuan Chen, Xing Zhao, Ze Han, Bingjie |
author_sort | Zhao, Yi |
collection | PubMed |
description | Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the overexpressed efflux pumps, the infiltration, invasion, high heterogeneity of tumor cells, drug resistance and immune escape caused by tumor microenvironment (TME) and cancer stem cells (CSC). This review attempts to clarify the challenges for multi-functional nano drug delivery systems (NDDS) to cross the BBB and target the cancer cells or organelles, and also provides a brief description of the different types of targeted multi-functional NDDS that have shown potential for success in delivering drugs to the brain. Further, this review also summarizes the research progress of multi-functional NDDS in the combination therapy of brain tumors from the following sections, the combination of chemotherapy drugs, chemotherapy-chemodynamic combination therapy, chemotherapy-immunization combination therapy, and chemotherapy-gene combination therapy. We also provide an insight into the recent advances in designing multi-functional NDDS for combination therapy. |
format | Online Article Text |
id | pubmed-9828736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-98287362023-01-10 Recent advances in drug delivery systems for targeting brain tumors Zhao, Yi Yue, Ping Peng, Yao Sun, Yuanyuan Chen, Xing Zhao, Ze Han, Bingjie Drug Deliv Research Article Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the median survival for brain tumor patients is only about 20 months. The treatment for brain tumor still faces many challenges, such as the blood-brain barrier (BBB), blood-brain tumor barrier (BBTB), the overexpressed efflux pumps, the infiltration, invasion, high heterogeneity of tumor cells, drug resistance and immune escape caused by tumor microenvironment (TME) and cancer stem cells (CSC). This review attempts to clarify the challenges for multi-functional nano drug delivery systems (NDDS) to cross the BBB and target the cancer cells or organelles, and also provides a brief description of the different types of targeted multi-functional NDDS that have shown potential for success in delivering drugs to the brain. Further, this review also summarizes the research progress of multi-functional NDDS in the combination therapy of brain tumors from the following sections, the combination of chemotherapy drugs, chemotherapy-chemodynamic combination therapy, chemotherapy-immunization combination therapy, and chemotherapy-gene combination therapy. We also provide an insight into the recent advances in designing multi-functional NDDS for combination therapy. Taylor & Francis 2023-01-03 /pmc/articles/PMC9828736/ /pubmed/36597214 http://dx.doi.org/10.1080/10717544.2022.2154409 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhao, Yi Yue, Ping Peng, Yao Sun, Yuanyuan Chen, Xing Zhao, Ze Han, Bingjie Recent advances in drug delivery systems for targeting brain tumors |
title | Recent advances in drug delivery systems for targeting brain tumors |
title_full | Recent advances in drug delivery systems for targeting brain tumors |
title_fullStr | Recent advances in drug delivery systems for targeting brain tumors |
title_full_unstemmed | Recent advances in drug delivery systems for targeting brain tumors |
title_short | Recent advances in drug delivery systems for targeting brain tumors |
title_sort | recent advances in drug delivery systems for targeting brain tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828736/ https://www.ncbi.nlm.nih.gov/pubmed/36597214 http://dx.doi.org/10.1080/10717544.2022.2154409 |
work_keys_str_mv | AT zhaoyi recentadvancesindrugdeliverysystemsfortargetingbraintumors AT yueping recentadvancesindrugdeliverysystemsfortargetingbraintumors AT pengyao recentadvancesindrugdeliverysystemsfortargetingbraintumors AT sunyuanyuan recentadvancesindrugdeliverysystemsfortargetingbraintumors AT chenxing recentadvancesindrugdeliverysystemsfortargetingbraintumors AT zhaoze recentadvancesindrugdeliverysystemsfortargetingbraintumors AT hanbingjie recentadvancesindrugdeliverysystemsfortargetingbraintumors |